Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sebetralstat in Pediatric Patients With Hereditary Angioedema Type I or II
NCT06467084Phase 3Completed
- Sponsor
- KalVista Pharmaceuticals
- Start
- Aug 2024
- Primary completion
- Jan 2026
- Modality
- Small Molecules
- Countries
- 7
01
Overview
A Phase 3 trial of sebetralstat in hereditary angioedema (HAE), sponsored by KalVista Pharmaceuticals. Started Aug 2024; status: completed.
02
Drugs
sebetralstat
03
Conditions
hereditary angioedema (HAE)
Beyond the preview
Go deeper on NCT06467084.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06467084.